Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01498978
Title Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

prostate adenocarcinoma

Therapies

Ipilimumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
OHSU Knight Cancer Institute Portland Oregon 97239 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field